SEC Form SC 13D/A filed by Entasis Therapeutics Holdings Inc. (Amendment)
(Amendment No. 7)*
ENTASIS THERAPEUTICS HOLDINGS INC.
|
(Name of Issuer)
|
Common Stock, $0.001 par value
|
(Title of Class of Securities)
|
293614 103
|
(CUSIP Number)
|
Pavel Raifeld
Chief Executive Officer
Innoviva, Inc.
1350 Old Bayshore Highway Suite 400
Burlingame, CA
877-202-1097
|
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
|
February 17, 2022
|
(Date of Event which Requires Filing of this Statement)
|
*
|
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
|
1
|
NAME OF REPORTING PERSON
Innoviva, Inc.
|
||||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐
(b) ☐
|
||||
3
|
SEC USE ONLY
|
||||
4
|
SOURCE OF FUNDS
WC
|
||||
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
|
||||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
||||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
37,345,794(1)
|
|||
8
|
SHARED VOTING POWER
20,000,000(2)
|
||||
9
|
SOLE DISPOSITIVE POWER
37,345,794(1)
|
||||
10
|
SHARED DISPOSITIVE POWER
20,000,000(2)
|
||||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
57,345,794
|
||||
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
|
||||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
75.15%(3)
|
||||
14
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
|
||||
(1)
|
Includes shares of Common Stock and warrants to purchase Common Stock acquired by INVA on April 22, 2020, June 11, 2020, and September 1, 2020.
|
||||
(2)
|
Includes shares of Common Stock and warrants to purchase Common Stock acquired by ISO on May 3, 2021 and June 11, 2021.
|
||||
(3)
|
Based on 47,637,629 shares of Common Stock outstanding as of November 1, 2021, as reported by the Issuer in its Form 10-Q filed on November 4, 2021
plus warrants to purchase 28,672,897 shares of Common Stock previously acquired by the Reporting Persons.
|
1
|
NAME OF REPORTING PERSON
Innoviva Strategic Opportunities LLC
|
||||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐
(b) ☐
|
||||
3
|
SEC USE ONLY
|
||||
4
|
SOURCE OF FUNDS
WC
|
||||
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
|
||||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
||||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
0
|
|||
8
|
SHARED VOTING POWER
20,000,000(1)
|
||||
9
|
SOLE DISPOSITIVE POWER
0
|
||||
10
|
SHARED DISPOSITIVE POWER
20,000,000(1)
|
||||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
20,000,000
|
||||
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
|
||||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
34.7%(2)
|
||||
14
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
OO
|
||||
(1)
|
Includes shares of Common Stock and warrants to purchase Common Stock acquired by ISO on May 3, 2021 and June 11, 2021.
|
||||
(2)
|
Based on 47,637,629 shares of Common Stock outstanding as of November 1, 2021, as reported by the Issuer in its Form 10-Q filed on November 4, 2021
plus warrants to purchase 10,000,000 shares of Common Stock previously acquired by the Reporting Persons.
|
By: Innoviva, Inc., its managing member